Electrostatic Similarity Analysis of Human β-Defensin Binding in the Melanocortin System  by Nix, Matthew A. et al.
1946 Biophysical Journal Volume 109 November 2015 1946–1958ArticleElectrostatic Similarity Analysis of Human b-Defensin Binding in the
Melanocortin SystemMatthew A. Nix,1 Christopher B. Kaelin,2,3 Rafael Palomino,1 Jillian L. Miller,1 Gregory S. Barsh,2,3,*
and Glenn L. Millhauser1,*
1Department of Chemistry and Biochemistry, University of California, Santa Cruz, Santa Cruz, California; 2HudsonAlpha Institute for
Biotechnology, Huntsville, Alabama; and 3Department of Genetics, Stanford University, Stanford, CaliforniaSUMMARY The b-defensins are a class of small cationic proteins that serve as components of numerous systems in verte-
brate biology, including the immune and melanocortin systems. Human b-defensin 3 (HBD3), which is produced in the skin,
has been found to bind to melanocortin receptors 1 and 4 through complementary electrostatics, a unique mechanism of
ligand-receptor interaction. This finding indicates that electrostatics alone, and not specific amino acid contact points, could
be sufficient for function in this ligand-receptor system, and further suggests that other small peptide ligands could interact
with these receptors in a similar fashion. Here, we conducted molecular-similarity analyses and functional studies of additional
members of the human b-defensin family, examining their potential as ligands of melanocortin-1 receptor, through selection
based on their electrostatic similarity to HBD3. Using Poisson-Boltzmann electrostatic calculations and molecular-similarity
analysis, we identified members of the human b-defensin family that are both similar and dissimilar to HBD3 in terms of elec-
trostatic potential. Synthesis and functional testing of a subset of these b-defensins showed that peptides with an HBD3-like
electrostatic character bound to melanocortin receptors with high affinity, whereas those that were anticorrelated to HBD3
showed no binding affinity. These findings expand on the central role of electrostatics in the control of this ligand-receptor system
and further demonstrate the utility of employing molecular-similarity analysis. Additionally, we identified several new potential
ligands of melanocortin-1 receptor, which may have implications for our understanding of the role defensins play in melanocortin
physiology.INTRODUCTIONb-defensins are small cationic, disulfide-rich proteins of
the innate and adaptive immune system that are capable
of signaling at melanocortin receptors (MCRs) (1-3). In
the melanocortin system, a collection of G-protein-
coupled receptors (GPCRs) and their ligands act together
to regulate diverse physiological phenomena, including
pigmentation, adrenal function, and appetite (4). As
GPCRs, the MCRs transmit signals by coupling to intra-
cellular G proteins and, as shown recently for MC4R,
inward rectifying potassium channels (5). At melanocor-
tin-1 receptor (Mc1r), which is located in the skin, agonist
binding stimulates receptor activation and cyclic AMP
production, leading to the synthesis of black/brown eume-
lanin pigment (6,7). Conversely, inverse-agonist binding
at Mc1r decreases receptor signaling and cyclic AMP
production, leading to the synthesis of red/yellow pheome-
lanin pigment (8). At melanocortin-4 receptor (Mc4r),
which is found in the hypothalamus, receptor activation
leads to a decrease in appetite while a reduction in recep-
tor signaling leads to increased appetite. The classic mel-
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0006-3495/15/11/1946/13the agonist a-melanocyte stimulating hormone (a-MSH)
and the inverse agonists Agouti signaling protein (ASIP)
and Agouti-related protein (AgRP), all bind through a
well-characterized linear motif of positively charged and
aromatic residues, HFRW and RFF, respectively (9-12).
Previously, we characterized the newest ligand that is
capable of modulating melanocortin signaling, canine
b-defensin 3 (CBD103), solving a long-standing mystery
regarding the dominant inheritance of black coat color
in domestic dogs (2). More recently, we performed a
structure-function analysis of the human ortholog of
CBD103, human b-defensin 3 (HBD3), to determine the
physicochemical properties that confer its high-affinity
binding to the MCRs (13). Our analysis of HBD3 uncov-
ered a mechanism for receptor binding that operates in a
fundamentally different way than all previously character-
ized melanocortin ligands. Surprisingly, we found that
HBD3 does not rely on any comparable positive-aromatic
sequence for receptor binding, such as that found in
the melanocortins ASIP and AgRP, but instead depends
on electrostatic complementarity between the positively
charged b-defensin peptide surface and the negatively
charged MCR exo-loops.
Historically the discovery of melanocortin ligands
and receptors, including HBD3, has been coupled tohttp://dx.doi.org/10.1016/j.bpj.2015.09.005
b-Defensin Electrostatics 1947phenotype-driven pigmentation research. This approach uti-
lizes model organisms that possess unique and identifiable
coat-color phenotypes, enabling genetic linkage mapping
and pedigree analysis to pinpoint the responsible genetic
elements. Therefore, the genetic relationships among mela-
nocortin-system member proteins were well understood
before their molecular and structural details were eluci-
dated. One alternative protein-structure-based method for
finding molecules with a specific function is molecular-sim-
ilarity analysis, which is based on the fundamental concept
that molecules with similar physicochemical properties will
exhibit similar behaviors and functions (14). Molecular-
similarity tools, which were originally developed in the
field of medicinal chemistry for in silico screening of
small-molecule drug candidates, have more recently been
adapted for use with larger, more complex biomolecules
(14). The application of molecular-similarity analysis,
coupled with experimental data, can serve as a valuable
search tool for discovering new molecules with specific ac-
tivity and provide deeper insight into the physicochemical
requirements that define their function. From this perspec-
tive, and because of the unique electrostatic binding mode
employed by HBD3 and the MCRs, we postulated that other
b-defensin peptides with properties similar to those of
HBD3 might also bind to and signal at the MCRs.
In this study, we performed a molecular-similarity analysis
of all known human b-defensin sequences, obtained from
the UniProt database, and tested a subset of them for their
binding properties at theMCRs. Using the Protein Interaction
Property Similarity Analysis (PIPSA) computational tool,
which combines Poisson-Boltzmann electrostatic calcula-
tions with molecular-similarity analysis, we obtained results
that allowed us to categorize b-defensins based on their
similarity to the electrostatic potential of HBD3 (15,16). We
synthesized and tested a subset of these peptides and found
that b-defensins with HBD3-like electrostatic potentials
bound with high affinity to Mc1r, whereas b-defensins that
were highly dissimilar to HBD3 did not display any affinity.
As a result, our investigation identified several new (to our
knowledge) potential ligands, some with remarkably high
affinity, thatmayhave a relevant signaling function in themel-
anocortin system. Furthermore, our analysis established the
utility of in silico electrostatic similaritymethods for discrim-
inating binding function at these receptors. Together, our find-
ings demonstrate that electrostatic potential alone is a primary
binding determinant in the melanocortin system, which may
lead to further insights into the relationship between b-defen-
sins and melanocortin signaling.MATERIALS AND METHODS
Protein modeling
All protein models used in this study were generated using the program
Modeler, version 9.9 (17). Human b-defensin sequences were obtainedfrom the Universal Protein Resource (UniProt) database (18). All se-
quences with unknown structures (29 of 32) were aligned to the HBD3
sequence utilizing Modeler’s align2d alignment routine. When alignment
was poor due to low sequence similarity between the target defensin and
HBD3, the two sequences were manually aligned using the six canonical
cysteine residues present in both sequences as a guide. Aligned sequences
were truncated to reflect the approximate length of HBD3. When neces-
sary, sequences were truncated 10 amino acids N-terminal of the first
cysteine and four amino acids C-terminal to the last cysteine. Using the
sequence alignment and one randomly chosen NMR model from the pub-
lished HBD3 structure (PDB ID: 1kj6) as a structural template, we gener-
ated new defensin models using Modeler’s automodel routine. We aligned
all of the generated b-defensin structures to the HBD3 structure using the
Matchmaker tool in Chimera, and saved their PDB coordinates before us-
ing them in molecular-similarity calculations (19). Note that our subse-
quent calculations did not depend on which low-energy NMR structures
we chose from 1kj6.Electrostatic calculations and similarity analysis
The electrostatic calculations and similarity analysis were performed us-
ing the PIPSA software package (15,16). All b-defensin PDB structure
files (both homology modeled and obtained from the PDB database)
were converted to PQR files using the PDB2PQR program with an
AMBER force field. The protonation state of the titratable amino acids
was automatically assigned using the program PROKPA (a component
of the PDB2PQR program) and was performed at pH 7.0. Electrostatic
potentials were calculated using the adaptive Poisson-Boltzmann solver
(APBS) and the similarity analysis was performed by PIPSA (20,21).
The APBS and environmental parameters included a grid spacing of
1 A˚, a simulated temperature of 300 K, and a 50 mM solvent ionic
strength. A 50 mM solvent ionic strength was chosen primarily for con-
venience (the default setting in PIPSA) but also as an intermediate value
between a 0 mM strength (which may overemphasize differences electro-
statically) and a 150 mM strength (which would decrease the electro-
static difference and compress the similarity comparison). A similarity
analysis utilizing variable ionic strength values did not significantly alter
the electrostatic ranking. The solvent dielectric constant was set to 78
and the protein interior dielectric constant was 2. The Hodgkin electro-
static similarity index (ESI) and Carbo ESI were calculated and sub-
jected to a complete cluster analysis using the statistical program R
(22,23). Although we calculated both the Hodgkin and Carbo indices,
in this study we report only the Hodgkin indices. This is primarily
because Hodgkin indices (according to the form of the equation) are
more sensitive to differences in both the magnitude and form of the elec-
trostatic potential, whereas Carbo indices are sensitive to form but not
magnitude.Peptide synthesis
All peptides were produced on a CEM Liberty1 microwave peptide syn-
thesizer using standard Fmoc chemistry. Amino acids were purchased
from Aapptec and assembled on H-Rink amide ChemMatrix resin pur-
chased from Aldrich. Fmoc protecting groups were removed using 20%
piperidine with 0.1 M hydroxybenzotriazole in dimethylformamide.
Amino acids were coupled using 5 molar equivalents of diisopropylcar-
bodiimide and 10 molar equivalents of hydroxybenzotriazole in dimethyl-
formamide. N-terminal capping was achieved when necessary with a 10%
solution of acetic anhydride. Cleavage of the peptide from the resin was
performed in a mixture of TFA/TIS/EDT/phenol (90:4:4:2) for 90 min.
Crude products were purified by preparative reverse-phase high-perfor-
mance liquid chromatography (RP-HPLC) and identified by electrospray
ionization mass spectrometry before they were subjected to oxidative
folding reactions. Quantitative concentrations were determined via aminoBiophysical Journal 109(9) 1946–1958
1948 Nix et al.acid analysis at the Molecular Structure Facility, University of California,
Davis.Oxidative peptide folding and characterization
To produce folded peptides with the native b-defensin disulfide bond con-
nectivity of Cys-1-5, Cys-2-4, and Cys-3-6, all peptides were folded using
either a full-orthogonal or semiorthogonal cysteine protection scheme. For
peptides produced with full-orthogonal cysteine protection, including
HBD3, HBD2, defb29, and defb28, disulfides were formed according to
previously published protocols (24). Briefly, peptides were synthesized us-
ing three different cysteine precursors with orthogonal side-chain protect-
ing groups. Cys-1 and Cys-5 were protected with the standard Trityl
protecting group, which is removed during the initial TFA cleavage step
that removes the peptide from the resin. Cys-2 and Cys-4 were protected
using the acetamidomethyl (Acm) protecting group, and Cys-3 and Cys-6
were protected with the tert-butyl protecting group. The first disulfide
(Cys-1-5) was formed using an oxidative folding solution consisting of
50% acetonitrile and 50% water, set to pH 8.0 with ammonium hydroxide.
The peptide concentration was typically 0.5 mg/mL. The reaction mixture
was stirred overnight at room temperature, followed by lyophilization. The
resulting product showed a mass loss of 2 amu as well as resistance to
the sulfhydryl alkylating agent N-ethylmaleimide (NEM), consistent with
the formation of a single disulfide bond. The second disulfide (Cys-2-4)
was formed by dissolving the lyophilized product in a 4:1 ratio of glacial
acetic acid and 0.1 M HCl to a final concentration of 0.5 mg/mL, followed
by the addition of 20 molar equivalents of iodine in glacial acetic acid,
which simultaneously removes the Acm protecting group and oxidizes
the disulfide (25). The reaction mixture was stirred for 90 min and then
quenched by the addition of excess ascorbic acid, and purified by RP-
HPLC. The resulting single product showed a mass loss of 144 amu and
resistance to NEM modification, consistent with the removal of two Acm
protecting groups and the formation of the second disulfide bond. The third
and final disulfide (Cys-3-6) was formed by dissolving the peptide to a final
concentration of 2 mg/mL in neat TFAwith 40 molar equivalents of anisole
and 100–300 molar equivalents of either DMSO or diphenyl sulfoxide,
which simultaneously removes the tert-butyl protecting group and oxidizes
the disulfide. When we used diphenyl sulfoxide, we additionally added 150
equivalents of methyltrichlorosilane to catalyze the reaction (26). The reac-
tion mixture was stirred for 1–2 h at room temperature and quenched by
adding excess ice-cold ether to precipitate the peptide. The precipitate
was redissolved and purified by RP-HPLC, and the resulting single product
showed a mass loss of 114 amu, consistent with the removal of the tert-butyl
protecting groups and formation of the final disulfide bond. For peptides
containing a tryptophan residue, including defb25, defb23, defb18, and
defb4, we resorted to a semiorthogonal protection scheme due to these res-
idues’ susceptibility to modification during the removal of the tert-butyl
protecting groups. Under this methodology, Cys-2, -3, -4, and -6 were pro-
tected using the Trt protecting group, and Cys-1 and -5 were protected with
the Acm protecting group. With this method, the number of disulfide bond
combinations was reduced from 15 to three, with one of the three represent-
ing the native connectivity. The first two disulfide bonds were formed using
our standard folding buffer of 10%DMSO, 1.6 M guanidine HCl, and 0.1 M
Tris at pH 8.5. Purification by RP-HPLC typically resulted in two or three
separable peaks with identical oxidized mass, indicating the presence of
most or all combinations of the four free thiols oxidized into two disulfide
bonds. To determine which species had the native connectivity of Cys-2-4
and Cys-3-6, we subjected each isolated peak to partial reduction, NEM
modification, protease digestion, and fragment identification by matrix-as-
sisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spec-
trometry. Briefly, ~50 mg of peptide was subjected to partial reducing
conditions in 100 mM Tris buffer, pH 5.0, with 1 molar equivalent of the
mild reducing agent tris(2-carboxyethyl)phosphine hydrochloride for
15 min at room temperature. A large excess of NEM was then added to
the mixture and allowed to incubate for another 15 min before purificationBiophysical Journal 109(9) 1946–1958by RP-HPLC. The product corresponding to a single disulfide reduction and
modification, as identified by a mass increase of 125 amu per thiol, was iso-
lated and lyophilized. The sample was then fully reduced with 20 mM di-
thiothreitol for 1 h at 37C and incubated with one of several proteases
(Arg-C, Lys-C, trypsin, and chymotrypsin, all provided by Princeton Sepa-
rations, Freehold Township, NJ) overnight at room temperature to allow for
full digestion of the peptide before mass spectrometry analysis (Ettan
MALDI-TOF Pro; Amersham Biosciences). Peptide digests and standard
mass controls (angiotensin III and adrenocorticotropic hormone) were
mixed in a 1:1 ratio with a saturated solution of a-cyano-4-hydroxycin-
namic acid matrix compound on MALDI plates. MALDI-TOF analysis
was accomplished using a 20 kV acceleration potential in positive ion
mode, with both reflectron and linear scanning modes. Digest fragments
were predicted by the autodigest simulation tool in Mass Lynx (Waters),
accounting for both NEM and Acm cysteine modifications. Since the
Acm-protected cysteines did not participate in the initial oxidative fold,
we determined the connectivities by identifying matching free thiol or
NEM digest fragments. After identifying the species that possessed native
b-defensin disulfide connectivity, we formed the final disulfide between
Cys-1 and Cys-5 using the previously mentioned reaction with iodine in
glacial acetic acid. All folded peptides were purified by RP-HPLC and iden-
tified as fully oxidized peptides by mass spectrometry.Competitive binding assays
Receptor-ligand binding assays were performed using the DELPHIA
lanthanide-based detection system on intact human embryonic kidney
(HEK) 293T cells transiently transfected with MCR expression constructs
as previously described (2).RESULTS
b-defensin structural modeling
A prerequisite for performing a molecular-similarity anal-
ysis is to obtain 3D coordinates of the proteins of interest
by either direct structure determination or homology
modeling. In the human b-defensin protein family, only
four of the 32 known members (HBD1, HBD2, HBD3,
and HBD6) have solved structures (27-30). Therefore, we
performed homology modeling on all b-defensins of un-
known structure using the Modeler program, utilizing
HBD3 as a structural template. One difficulty we anticipated
was the lack of primary sequence similarity within the b-de-
fensin family, which is a requirement for sequence align-
ment between the protein to be modeled and the structural
template. However, the b-defensins are classified together
primarily because of their highly conserved cysteine spacing
and disulfide topology, which gives rise to their character-
istic fold. The profound influence of the disulfides is seen
in three of the b-defensins of known structure insofar as
they share little primary sequence similarity, yet remarkably
adopt nearly identical folds (Fig. 1) (31). Therefore, the
alignment of the cysteines appeared to be the most critical
aspect for generating accurate homology models of each de-
fensin. In light of this, we inspected each alignment result to
confirm that all cysteine residues of the target and template
sequence were aligned properly before proceeding with the
modeling calculations. When the cysteines did not align, we
FIGURE 1 b-defensin structures and sequences.
(A) Structures of HBD1 (PDB ID: 1KJ5), HBD2
(PDB ID: 1FD3), and HBD3 (PDB ID: 1KJ6),
shown from left to right. Purple, b-strands; red,
a-helices; yellow, disulfide bonds. (B) Multiple
sequence alignment of the same three b-defensins,
highlighting the conserved residues in red.
b-Defensin Electrostatics 1949manually altered the alignment to match them exactly so as
to produce structural models that were restrained by these
conserved disulfide bonds.
Another consideration for our modeling analyses was that
b-defensin sequences vary in length from 36 to more than
100 residues, with extended polypeptide segments outside
of the cysteine-rich core (Fig. S1 in the Supporting Mate-
rial). Consequently, when we initially generated models of
the longer sequences, they maintained the typical b-defensin
fold induced by the cysteine alignment, but usually had long
tails of unknown structure on the N-terminus, C-terminus, or
both. We therefore utilized N- or C-terminal truncated ver-
sions of these longer b-defensins for modeling and molecu-
lar-similarity analysis, as well as for functional testing. We
employed this strategy for two reasons. First, to test our
electrostatic binding model, we hypothesized that only the
folded core component of each b-defensin was necessary.
In our previous analysis of HBD3, nearly all of the charged
residues required for high-affinity receptor binding were
contained in the folded core region, bracketed by the ter-
minal cysteines, and imposed by the disulfide bonds (2).
Second, the majority of the amino acid sequences we ob-
tained from the UniProt database are inferred from evidence
at the transcription level, which may not accurately reflect
the sequence of the final mature form of the protein (32).
All three of the b-defensins detected at the protein level
have very short N- and C-terminal sequence lengths beyond
their six-cysteine core, suggesting that this folded segment
alone is sufficient for function. We therefore truncated the
longer b-defensin sequences using the native length of
HBD3 as our guide. With HBD3, the N-terminus originates10 residues before the first cysteine, and the C-terminus ex-
tends four amino acids beyond the last of the six canonical
cysteines (Fig. 1 B). To retain a similarly sized folded core
for the new b-defensins, we truncated the N- and C-termini
of each peptide sequence in a fashion identical to that em-
ployed for HBD3 when it was necessary to do so. Fig. 2
shows the truncated b-defensin sequences that were used
in this study. After generating 3D models for the set of b-de-
fensins, we visually inspected each result to ensure a reason-
ably folded structure for the new defensin. We also aligned
each model to the PDB coordinates of HBD3 using the
Chimera molecular viewing program and its Matchmaker
function, which is a necessary step to accurately perform
similarity analyses.PIPSA molecular-similarity analysis
The use of molecular-similarity analysis to classify mole-
cules with a particular chemical behavior is a common prac-
tice in small-molecule medicinal chemistry (33). More
recently, molecular-similarity analysis has been adapted
for use with larger, more complex biomolecules such as
DNA and proteins. This method aims to use computer-aided
comparisons of molecular properties to predict the biolog-
ical activity of uncharacterized molecules. In general, the
application of molecular-similarity methods requires the
investigator to make several key choices. First, one must
choose an appropriate molecular descriptor that accurately
captures the relevant physicochemical qualities of the mol-
ecules in question. Molecular descriptors in medicinal
chemistry applications can range widely from simpleBiophysical Journal 109(9) 1946–1958
FIGURE 2 Multiple sequence alignment of all
truncated human b-defensins employed in this
study. When it was necessary, the N-terminus of
each new defensin was truncated 10 amino acids
before the first cysteine residue, and the C-terminus
was truncated four amino acids after the last
cysteine, which is similar to the length of mature
HBD3.
1950 Nix et al.macroscopic properties such as molecular weight (and
others similar to Lipinski’s rule of five) to calculated 3D sur-
face properties such as electrostatic potential or hydropho-
bicity (34-36). The descriptor employed is usually chosen
based on prior knowledge of important molecular character-
istics of the system being studied. Second, one must choose
a method for comparing molecular descriptors, called simi-
larity metrics (37,38). This typically involves mathematical
comparisons of the molecular descriptors of two molecules.
The output of a similarity metric operation between a
descriptor of two molecules is a single numerical value
that captures the extent of similarity between them. Finally,
in addition to descriptors and metrics, one must choose a
mechanism to select molecules that are predicted to exhibit
a given chemical behavior. This requires prior knowledge
regarding the mechanism of interest in a given system,
such as a typical binding mode of a known molecule (an
important characteristic that gives a molecule function), or
details about the chemical nature of a ligand-binding or
enzymatic site.
Our previous structure-function analysis of HBD3 (13)
suggested that charge complementarity is the main driving
force behind its binding affinity for the MCRs. Therefore,
the electrostatic potential of the b-defensins served as our
molecular descriptor, with the additional hypothesis that
similarity to HBD3 would confer high-affinity binding to
the MCRs. The current method for estimating the electro-
static characteristics of proteins involves solving the linear-
ized Poisson-Boltzmann (LPB) equation of a 3D model of
the biomolecule (39-42). APBS is a stand-alone softwareBiophysical Journal 109(9) 1946–1958application that is capable of solving the LPB equation for
any biomolecule, but it can also be incorporated into other
molecular viewing programs as a plug-in (Pymol) or in
the computational stream of larger software applications
(20).
We chose to use the PIPSA computational tool to
perform all aspects of our molecular-similarity analysis.
This program incorporates the APBS program to solve
the LPB equation, as well as other software components
to perform molecular-similarity and cluster analyses of
the electrostatic results. We proceeded to perform our
molecular-similarity analysis on all 32 human b-defensins
using the three known structures (HBD1–3) and our
Modeler-generated models.
Fig. 3 displays the results of our PIPSA cluster analysis as
a dendrogram, with b-defensin groupings exhibiting a range
of electrostatic similarities to HBD3 and to each other.
In general, the analysis identified two distinct, high-level
clusters, and each cluster was further subdivided to form a
total of four major clusters, with the first containing
HBD3 (cluster 1). Unsurprisingly, the majority of b-defen-
sins that clustered together with HBD3 (net charge þ11)
possessed some of the highest net-positive charges in the
entire family. We also found several b-defensins that were
very dissimilar to those found in cluster 1, some of which
were electrostatically anticorrelated to HBD3 according
to their ESI scores (cluster 4). Interestingly, several of
the peptides in clusters 3 and 4 had net charges similar
to those of the b-defensins found in clusters 1 and 2,
emphasizing the importance of the arrangement of charged
defensin charge 
defb15 6
defb4 6
defb27 4
defb35 5
defb6 4
hbd3 11
defb23 9
hbd2 6
defb19 6
defb28 8
defb30 4
defb32 3
defb21 4
defb32 3
hbd1 4
defb18 5
defb25 5
defb14 0
defb29 5
defb33 2
defb5 2
defb26 4
defb9 2
defb13 2
defb11 1
defb12 2
defb7 4
defb8 0
defb31 -1
defb16 2
defb24 1
defb34 0
cluster 1 
cluster 2 
cluster 3 
cluster 4 
4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 
FIGURE 3 PIPSA ESIs displayed as a dendro-
gram. The electrostatic potentials of all 32 trun-
cated human b-defensins were compared with
each other using Hodgkin ESIs. Each peptide’s
net charge is shown next to its identifier. The loca-
tion of HBD3 in the cluster analysis is highlighted
in gray. The peptides grouped into four distinct
clusters, as marked above, according to complete
cluster analysis using the R program. Peptides
selected for synthesis and functional testing are
highlighted in bold.
b-Defensin Electrostatics 1951residues in forming the electrostatic potential field of a pro-
tein and not simply the total charge.
Although the dendrogram method of analysis provides
unbiased insight into the electrostatic relatedness of a
group as a whole, we were primarily interested in deter-
mining each peptide’s specific electrostatic similarity
to HBD3. Fig. 4 displays the raw Hodgkin ESI scores
for all b-defensins relative only to HBD3, ranging from
1 (complete similarity) to 1 (complete dissimilarity).
According to this method of parsing the data, several pep-
tides that were located in clusters other than cluster 1
(HBD3’s cluster) are now shown to have electrostatics
highly similar to those of HBD3. We selected several pep-
tides from our analysis for synthesis and functional testing,
including defb4, defb23, and hbd2 from cluster 1; defb28,
defb18, defb25, and defb29 from cluster 2; defb11 from
cluster 3; and defb7 from cluster 4 (Figs. 3 and 4). We
selected defb7 because it lacks the first Cys residue and
therefore serves as a test of the influence of disulfide
cross-links. To establish positive controls for our bindingassay, we synthesized and tested HBD3 as well as ASIP-
YY, a modified synthetic variant of ASIP that possesses
improved folding characteristics (43). Both HBD3 and
ASIP-YY have well-established binding constants at
Mc1r and Mc4r, falling in the nanomolar range (2). This
provided us with a direct comparison to judge the binding
affinity of new b-defensins relative to peptides with known
affinities.b-defensin folding
All b-defensin peptides were initially synthesized with free
thiols, enabling the use of conventional oxidative folding
techniques. After oxidation occurred, however, most of the
peptides gave multiple species according to HPLC, suggest-
ing a mixture of native and nonnative disulfide bond
arrangements. We considered using disulfide mapping to
identify the correctly folded species, but thought that would
be exceptionally challenging given the specific defensin
sequence and large number of observed conformers. WeBiophysical Journal 109(9) 1946–1958
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FIGURE 4 PIPSA Hodgkin ESIs for all b-de-
fensins relative to HBD3, ranging from þ1 (com-
plete similarity) to 1 (completely dissimilar).
HBD3 has an ESI of 1 (complete identity relative
to itself). The graph is sorted from highest
HBD3 similarity (top) to lowest HBD3 similarity
(bottom). The peptides chosen for synthesis and
functional testing are marked with an asterisk (*).
1952 Nix et al.therefore decided to synthesize all b-defensin peptides
with orthogonal cysteine-protecting groups, which would
allow us to selectively form the native b-defensin disulfide
connectivities of Cys-1-5, Cys-2-4, and Cys-3-6. When a
peptide sequence was incompatible with the reaction condi-
tions for removing the full-orthogonal cysteine protection
groups, we employed a semiorthogonal protection strategy
coupled with enzymatic digestion and mass spectrometry
to determine the disulfide connectivity (see Materials and
Methods). We were able to engineer or determine the native
disulfide connectivity for all peptides chosen for synthesis,
with the exception of defb4 and defb7. Although our initial
synthesis and folding of the free-thiol version of defb4
resulted in a single folded species of unknown disulfide
connectivity, we were unable to produce the full or semior-
thogonal version necessary to ensure native connectivity.
Nevertheless, we included the defb4 peptide in this study
with the caveat that its binding results may be inaccurate
due to alternative folded states (though we note anecdotally
that when multiple conformers were tested in previous
studies, they typically exhibited similar binding affinities).
In the case of defb7, the native sequence contains only
five of the six canonical cysteine residues (missing Cys-1).Biophysical Journal 109(9) 1946–1958To simplify the synthesis of this peptide, we replaced Cys-
5 with alanine, eliminating disulfide 1-5 altogether. The
two remaining native disulfide bonds were formed using
orthogonal protecting groups. Although the defb7 binding
results are included in this study, they must be considered
in the context of less structural rigidity than is assumed in
the modeled structure and electrostatic calculations.b-defensin pharmacology
Fig. 5 shows the results of binding assays for the ligands that
exhibited measurable affinity. The primary results of our
studies are summarized in Table 1. Of the seven b-defensins
selected from clusters 1 and 2, five bound to Mc1r with
affinities ranging from strong to moderate, with most Ki
values < 200 nM. Two exceptions were defb4 (cluster 1)
and defb18 (cluster 2). Defb4 had Ki values in the micro-
molar range, much weaker than all others in cluster 1. How-
ever, as noted above, the disulfide connectivity of this
peptide was uncertain, and its weaker binding may be due
to improper folding. Unlike other peptides from cluster 2,
defb18 exhibited no binding to Mc1r whatsoever. In contrast
to peptides from clusters 1 and 2, peptides from clusters 3
FIGURE 5 Competitive binding assays with
Mc1r. A subset of competition binding assay
curves in which varying amounts of unlabeled
synthetic b-defensins were added together with
Eu-NDP-MSH tracer to HEK293 cells transiently
transfected withMc1r. The logarithm of competing
ligand concentration is plotted on the abscissa and
the amount of Eu-NDP-MSH bound, measured as
relative fluorescence, is plotted on the ordinate.
b-Defensin Electrostatics 1953and 4 exhibited much weaker or no binding to Mc1r. Defb11
from cluster 3 displayed micromolar binding, whereas
defb7, lacking a disulfide bond, did not exhibit any appre-
ciable binding in our assay, which has an upper limit of
measurable Ki of ~9 mM. With the exception of defb4 and
defb18, we correctly predicted the Mc1r binding character-
istics of seven (out of nine) selected members of the b-de-
fensin family.
A visual comparison of the electrostatic surfaces of the
select b-defensins fails to reveal any obvious features that
distinguish high-affinity from low-affinity ligands (see
Figs. S2 and 7). In an attempt to correlate the electrostatic
properties of these peptides to their binding affinities, we
plotted Mc1r Ki versus two metrics: net charge and Hodgkin
ESI scores relative to HBD3 (Fig. 6). The correlation of net
charge to Ki was insignificant, indicating that charge is a
poor predictor of receptor binding (R ¼ 0.50, p ¼ 0.145).
By contrast, the correlation between the Hodgkin ESI and
Ki, while not strong, was moderately significant (R ¼
0.66, p ¼ 0.037). Despite this correlation, one conspicuous
discrepancy in the results strongly suggested inadequaciesTABLE 1 Mclr dissociation constants
Peptide Cluster Mc1r Ki (nM)
a Mean5 SE Charge
ASIP-YY NA 0.75 (0.13) 4
HBD3 1 33.0 11
defb4 1 3630.0 6
defb23 1 177.0 (25.4) 9
HBD2 1 22.9 (5.8) 6
defb28 2 35.2 (9.9) 8
defb18 2 NB 5
defb25 2 27.8 (7.8) 5
defb29 2 54.6 (15.1) 5
defb11 3 1581.4 (795.5) 1
defb7 4 NB 4
NB, no binding.
aAll displacement binding experiments were performed using Eu-NDP-
MSH as a competitor. Mean Ki values (in nM) were calculated by fitting
the data to a sigmoidal dose-response curve with variable slope. The
mean5 SE is reported in parentheses after each mean Ki value. All binding
experiments were performed in triplicate or greater.in either our analysis approach or the validity of our electro-
static binding model. Specifically, two peptides in our study,
defb18 and defb25, had similar ESI scores but showed
dramatically different behaviors at Mc1r. Both possess
identical net charges and nearly identical ESI scores, yet
defb18 exhibits no affinity for Mc1r, and defb25 exhibits a
Ki of 27.8 nM for the receptor. We suspected that these
two peptides may have been incorrectly assigned by our
initial PIPSA analysis, and therefore sought to explore a
more nuanced approach for the electrostatic and similarity
calculations.
Our original similarity analysis compared members
based on the entire surface area of the peptide structures,
specifically the web-PIPSA default 4 A˚ skin around the
entire solvent-accessible surface of each protein (16).
(Although 4 A˚ is the commonly used default value, we
note that a significantly different choice of skin thickness
may alter the similarity ordering shown in Fig. 4.) How-
ever, it is most likely the case that compact ligands such
as the b-defensins interact with Mc1r primarily through
one specific region of their solvent-accessible surface.
Therefore, our whole-surface analysis most likely weighs
relevant and nonrelevant surfaces of the ligands equally,
possibly skewing the overall similarity scoring result as it
pertains to receptor binding. By restricting the similarity
analysis solely to the relevant binding surface, we hoped
to improve the correlation between the ESI score and the
binding affinity. Unfortunately, the relevant binding surface
of our benchmark b-defensin HBD3 is currently unknown
and cannot be easily mapped by mutagenesis (13). How-
ever, this notion suggested that limiting our analysis to
quadrants of the b-defensin structures might improve the
electrostatic similarity scoring and its predictive power
with regard to receptor binding, while simultaneously
revealing the b-defensin binding surface that is most rele-
vant for receptor affinity.
To guide more targeted regional calculations, we visually
examined the electrostatic surfaces of defb18 and defb25 for
differences that might account for their distinct binding af-
finities. Our inspection revealed that the largest differenceBiophysical Journal 109(9) 1946–1958
FIGURE 6 Correlation plots of peptide metrics versus binding affinity.
(A) The net charge of the truncated version of each b-defensin tested is
plotted on the abscissa and the log of Ki is plotted on the ordinate. (B)
The Hodgkin ESI score for each b-defensin is plotted on the abscissa while
the log of Ki is plotted on the ordinate. The Hodgkin ESI score is a single
value ranging from 1 to 1, indicating how electrostatically similar each
b-defensin is to HBD3. HBD3 compared with itself (completely similar)
has an ESI of 1 (shown above on plot). Significance testing was performed
using the program R.
FIGURE 7 Electrostatic comparison of defb18 and defb25. (A and B)
APBS-calculated electrostatic potentials of each peptide, shown with (A)
a 1kT/e isocontour surface and (B) a solvent-accessible surface. Positive
potential is shown in blue and negative potential is shown in red. The
approximate shape and location of the 17 A˚ sphere where we performed
our north-quadrant-targeted molecular-similarity analysis are shown as
transparent dotted circles overlaid on the structures in (B).
1954 Nix et al.between the two peptides was found in one particular region
located on the north surface of the peptides as they are typi-
cally displayed. This region was approximately composed
of two loops originating from segments found around and
between Cys-2 and -3, and Cys-4 and -5, as well as a portion
of the N-terminal a-helix (Fig. 7 A). We considered that var-
iances in this region might account for the differences in
binding affinity, and therefore performed additional calcula-
tions, restricting our analysis to this particular quadrant
of the entire group of b-defensins. We performed our calcu-
lation using a sphere of 17 A˚ centered on a coordinate such
that only the north electrostatic surface of each peptide was
included in the similarity analysis (Fig. 7 B). Fig. 8 displaysBiophysical Journal 109(9) 1946–1958the results of our 17 A˚ sphere calculation as raw Hodgkin
ESI scores, and Fig. 9 displays the correlation plot of north
ESI values versus Mc1r Ki affinity. We observed a slight
resorting of the defb18 and defb25 peptides that more
closely aligned with their observed binding (new ESI scores
of 0.631 and 0.703, respectively), which contributed to a
modest improvement of the ESI/Mc1r Ki correlation (R ¼
0.71, p ¼ 0.022). By contrast, centering the same 17 A˚
sphere on the south region of the defensin structures demon-
strated deterioration in the ESI/Mc1r correlation (R ¼ 0.49,
p ¼ 0.155; data not shown). We also repeated this analysis
on two additional sections of the defensin structure we
termed the east and west quadrants (Fig. S3). Restricting
the similarity analysis to the west quadrant displayed a
poor correlation (R ¼ 0.56, p ¼ 0.092), whereas restricting
the analysis to the east quadrant displayed a moderate corre-
lation similar to the north-quadrant restriction (R ¼ 0.75,
p ¼ 0.012).DISCUSSION
All members of the melanocortin system were initially
discovered through phenotype-driven approaches, and their
genetic relationships with each other were established long
before the structural biology behind their interactions was
*
*
*
*
*
*
*
*
*
*
FIGURE 8 PIPSA Hodgkin ESIs for the north
quadrant.
b-Defensin Electrostatics 1955understood. Here, we present the results of an orthogonal
approach that is capable of identifying new ligands of this
receptor system based on molecular-similarity analysis.
This protein-sequence and structure-driven strategy also
provides a greater understanding of the molecular determi-
nants of MCR binding. By ranking b-defensins based on
their electrostatic similarity to HBD3, we correctly pre-
dicted the binding characteristics of seven out of nine select
peptides. Moreover, through this analysis, we discovered
five new (to our knowledge) Mc1r ligands with nanomolar
affinity. In contrast, our search for a simple metric that
drives a linear relationship between ESI and Ki was met
with only limited success.
Our exploration of the b-defensin family identified
several potential ligands for the melanocortin system, with
implications for the biological function of this broad family
of peptides. In humans, the b-defensins that we found to
have high Mc1r affinity are expressed in a range of epithelial
and other tissues, though several are exclusively found in the
male reproductive tract (1,44). The distribution of these pep-
tides, as well as their high affinity for Mc1r, suggests that
they may serve a physiologically relevant signaling function
in the melanocortin system. As Mc1r is known to operate in
pigmentation as well as the immune system, our resultsexpand the range of possible ligands that could modulate
either of these phenotypes.
From this emerging perspective of the b-defensins and
their dual capabilities as immune system molecules and li-
gands of Mc1r, our results might also explain certain mela-
nistic phenotypes in coat-bearing animals. For instance,
nearly 100% of the jaguars found on the Malaysian penin-
sula exhibit an all-black melanistic coat color, and one study
has linked this anomaly to dominant mutations of Mc1r
(45). However, it has been suggested that this coat color
may be due to signaling pathways shared between the mel-
anocortin and immune systems, and that melanistic coat co-
lor in some cases may be an artifact of past adaptions to
pathogenic challenge (46). Our findings suggest that several
members of the b-defensin family may account for the
fixation of black coat color in these cats and possibly other
animals with unexplained pigmentation effects. In this sce-
nario, altered expression patterns of b-defensins that may
have served as an adaptive response to microbial challenge
could have also resulted in the pleiotropic coat-color effects
observed today.
From a structural biology perspective, our findings also
demonstrate that electrostatics alone can be a major deter-
minant of MCR binding. Receptor-ligand interactions inBiophysical Journal 109(9) 1946–1958
FIGURE 9 North-quadrant Hodgkin ESIs versus log Ki correlation plot.
1956 Nix et al.the melanocortin system have typically been regarded as
highly specific events, requiring the positive-aromatic
pharmacophore that is present in most classic melanocor-
tin ligands. At least in the case of these b-defensin pep-
tides at Mc1r, a specific pharmacophore is not required,
demonstrating the expansive promiscuity of this receptor.
The peptides that bound Mc1r with high affinity share
only two common features: disulfide bond topology and
a specific arrangement of positively charged residues.
Although the primary sequence of each defensin is
different, according to our similarity analysis, the unique
arrangement of charged residues in each one generates a
similar positive electrostatic potential field. Although our
electrostatic analysis strongly implies that their Mc1r
binding capabilities are due to this common physicochem-
ical feature, the modest correlation between the Hodgkin
ESIs and Ki suggests that other important b-defensin
features are missing from our analysis. In contrast to
our electrostatic model of binding, a previous structural
investigation of heterodimer protein complexes showed
that charged residues such as Arg and Lys are typically
less abundant in the interface region, whereas aliphatic
and aromatic residues are enriched (47). Although the
MCRs may represent a unique case of protein-protein
interaction facilitated mostly by charged residues at the
interface, it may be that other residues that are not
captured by electrostatic analysis contribute to receptor
binding affinity.
It is certainly possible that our analysis can be improved
purely through computational means. As is the case in most
protein-protein interactions, the b-defensins most likelyBiophysical Journal 109(9) 1946–1958interface with the receptor using a specific peptide surface
region that is more critical for receptor affinity.
Our initial method of comparing electrostatic potentials
took into account the entire protein surface, which may
not be an ideal approach. Our targeted similarity analysis,
focusing roughly on four quadrants of the defensin structure,
demonstrated significant improvements in the correlation
between ESI and Mc1r Ki when we restricted the similarity
analysis to the north and east quadrants. Although these re-
sults are speculative, they suggest a general orientation of
the defensins relative to the receptors and that the relevant
surface necessary for their interaction lies somewhere
within this half of the protein. Further structural studies
will be required to confirm our proposed binding orientation
of these ligands at Mc1r.
These results may also provide insight into the binding
determinants of b-defensins in other receptor systems. In
this study, we found that HBD2 bound tightly to Mc1r
with an affinity similar to that of HBD3. Both HBD2 and
HBD3 have demonstrated anti-HIV properties, inhibiting
infection through direct interaction with the virus and pre-
venting its entry into cells by interaction with the chemo-
kine receptor CXCR4 (48,49). The structure of CXCR4
was recently published, and interestingly shows a ligand-
binding domain that is highly negative, similar to the
MCRs (50). The ligands and electrostatic features shared
by CXCR4 and the MCRs suggest to us that a similar elec-
trostatic interaction may operate between the b-defensins
and both receptor classes. Further work will be required
to determine the exact binding mechanism of either b-de-
fensin at CXCR4.
Our electrostatic analysis of b-defensins also demon-
strates the utility of in silico methods for discriminating
binding affinity in cases involving excessive and oppositely
charged molecules. Our analysis of the b-defensin family
covered only a small percentage of potential peptide ligands
available for consideration in the UniProt database. We
envision that, due to the loose requirements of MCR binding
we observed, several more ligands for these receptors may
exist and provide functionality in this system. By applying
electrostatic similarity analysis to a wider range of mole-
cules, investigators may be able to identify these ligands,
although improved methods for efficiently performing
such a large-scale analysis would be required.
Finally, the importance of electrostatics demonstrated
here also suggests that this feature could be used in
the design of new compounds for binding and activity
in the melanocortin system. Several groups have proposed
the electrostatic design or optimization of proteins when
excessive electrostatic complementarity is important for
system function (51-53). Several of these b-defensins bind
to other GPCRs, and electrostatics may similarly play a
part in their function. As such, this approach might also
be extended to other GPCR systems in which electrostatic
binding forces are dominant.
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